2011
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
Ruff CT, Morrow DA, Jarolim P, Ren F, Contant CF, Kaur A, Curtis SP, Laine L, Cannon CP, Brune K. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. The Journal Of Rheumatology 2011, 38: 1071-8. PMID: 21459935, DOI: 10.3899/jrheum.100880.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidBiomarkersC-Reactive ProteinCardiovascular DiseasesDiclofenacEtoricoxibFemaleHeart FailureHumansLongitudinal StudiesMaleMiddle AgedMyocardial InfarctionNatriuretic Peptide, BrainOsteoarthritisPeptide FragmentsProspective StudiesPyridinesRetrospective StudiesRisk FactorsSulfonesThrombosisTreatment OutcomeConceptsHigh-sensitivity C-reactive proteinNonsteroidal antiinflammatory drugsSensitivity C-reactive proteinNT-proBNPC-reactive proteinHeart failureCV eventsCV outcomesCV riskThrombotic eventsMyocardial infarctionAntiinflammatory drugsBiomarkers N-terminal pro-B-type natriuretic peptideCardiac biomarkers N-terminal pro-B-type natriuretic peptideN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideChronic nonsteroidal antiinflammatory drugsBaseline NT-proBNPChronic NSAID treatmentLow CV riskNT-proBNP levelsFuture cardiovascular eventsBody mass indexIdentification of patientsTypes of arthritis
2003
Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs1 1The Institute for Effectiveness Research, LLC, is a subsidiary of Medco Health Solutions, Inc., a Merck Company.
Laine L, Wogen J, Yu H. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs1 1The Institute for Effectiveness Research, LLC, is a subsidiary of Medco Health Solutions, Inc., a Merck Company. Gastroenterology 2003, 125: 389-395. PMID: 12891540, DOI: 10.1016/s0016-5085(03)00900-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Inflammatory Agents, Non-SteroidalCohort StudiesCost-Benefit AnalysisCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsFemaleGastrointestinal DiseasesHealth ResourcesHumansIsoenzymesLongitudinal StudiesMaleMembrane ProteinsMiddle AgedProstaglandin-Endoperoxide SynthasesRetrospective StudiesConceptsChronic NSAID therapyCoxib therapyNSAID therapyChronic nonsteroidal anti-inflammatory drug (NSAID) therapyNonsteroidal anti-inflammatory drug therapyAnti-inflammatory drug therapyHealth care resource utilizationCOX-2-specific inhibitorsU.S. administrative claims databaseMedco Health SolutionsProportion of patientsAdministrative claims databaseGastrointestinal eventsNewer coxibsInitial prescriptionChronic useClaims databaseDrug therapyClinical trialsDrug costsNew NSAIDClinical practicePatientsTherapyAbstractText